Vanda Pharmaceuticals Files 8-K on Shareholder Votes
Ticker: VNDA · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: VNDA
TL;DR
Vanda Pharma had a shareholder vote on June 5th. Details TBD.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on June 5, 2025, to report on matters submitted to a vote of its security holders. The filing does not detail the specific matters voted upon or the outcome of any such votes.
Why It Matters
This filing indicates that Vanda Pharmaceuticals held a vote of its security holders, which could pertain to significant corporate actions or governance matters.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any new financial or operational risks.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- June 5, 2025 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Vanda Pharmaceuticals' security holders on June 5, 2025?
The filing does not specify the exact matters voted upon, only that "Submission of Matters to a Vote of Security Holders" is the reported item.
What was the outcome of the shareholder vote reported in the 8-K?
The filing does not disclose the results or outcome of the shareholder vote.
Is this 8-K filing related to any new financing or debt issuance?
No, the filing is specifically for "Submission of Matters to a Vote of Security Holders" and does not mention financing or debt.
Does this filing indicate any changes in Vanda Pharmaceuticals' management or board of directors?
While shareholder votes can relate to director elections, this filing does not explicitly state that management or board changes were the subject of the vote.
Where is Vanda Pharmaceuticals Inc. headquartered?
Vanda Pharmaceuticals Inc. is headquartered at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Vanda Pharmaceuticals Inc. (VNDA).